Biotin

Most people taking biotin for hair growth are wasting their money and should stop, especially before any blood test. The only real signal is brittle nails (2.5mg daily increased nail thickness 25%, in small older trials), and hair growth evidence is essentially limited to people with confirmed deficiency or in multi-ingredient formulas where biotin cannot be isolated. The FDA has issued two safety communications (2017, 2019) because high-dose biotin skews lab assays, a patient died from a missed heart attack when troponin read falsely low. It also mimics Graves' disease on thyroid panels, triggering unnecessary scans, medications, and surgeries.

For hair growth, the evidence is substantially weaker. Reviews show that improvement occurs primarily in people with an underlying condition or confirmed biotin deficiency. There is a notable lack of quality trials showing benefit in healthy people with normal biotin levels. One important caveat: Trueb 2016 (PMID: 27601860, n=541 women with hair loss complaints) found 38% had measurable biotin deficiency (<100 ng/L serum biotin), suggesting subclinical deficiency may be more prevalent in dermatological populations than assumed. Trueb himself explicitly warned against treating hair loss indiscriminately with biotin and requires laboratory confirmation before supplementing.

Positive RCTs consumers cite are almost universally for multi-ingredient complexes, not biotin monotherapy. A 2021 double-blind RCT (PMC11694638, n=65) showed a 10.1% increase in terminal hair density vs a 2% decrease in placebo (p<0.001) - but the product contained biotin, zinc, tocotrienols, and astaxanthin. It is scientifically impossible to attribute that result to biotin specifically. Since biotin deficiency is rare in the general population, most healthy people taking biotin are unlikely to see measurable results.

An important safety concern rarely mentioned in marketing: high-dose biotin (above 5,000mcg) interferes with laboratory blood tests that use streptavidin-biotin technology. In sandwich assays (like troponin), biotin forces values falsely low - potentially masking an active heart attack. In competitive assays (like Free T4, Total T3, estradiol), biotin forces values falsely high. The FDA issued its first safety communication on November 28, 2017, directly triggered by a confirmed patient death from a missed myocardial infarction due to falsely low troponin. The FDA updated this warning in November 2019 with continued concern.

The clinical fallout is severe: the combination of falsely depressed TSH and falsely elevated Free T4/T3 perfectly mimics Graves' disease. Medical literature documents cases of euthyroid patients undergoing unnecessary radioactive iodine scans, being prescribed anti-thyroid medications, and even being scheduled for thyroidectomies - all due to biotin-induced lab artifacts. False PSA levels can also mask prostate cancer recurrence.

Mega-doses of 8,000-10,000mcg, common in the market, have no additional clinical support over the 2,500mcg dose used in research and carry significantly increased risk of lab interference and potential acne. Biotin has a half-life of approximately 2 hours; at standard nutritional doses (30-150 mcg), interference risk is virtually nonexistent. The danger is specific to supplement-level doses of 2,500mcg and above.